CSSETTufts Center for the Study of Drug Development **TUFTS CSDD INSIDER**January 2021

From the Director



Dear CSDD Friends,

This January Insider marks the beginning of my tenure as the Center's new director. It is a responsibility that comes at a critical point in time. Although last year was filled with uncertainty and significant challenge, we can all agree that it was also remarkable for its unprecedented collaboration, resiliency and innovation. In responding to the pandemic, all

aspects of drug development science, operations and regulation received greater visibility and attention, and offered compelling new insight into the possibilities for accelerating timelines and improving efficiencies and quality.

The CSDD team and I are very excited about the opportunities ahead. During the first half of 2021, we will publish the results of just-completed studies including new benchmarks on protocol design practices and their impact on clinical trial performance; operating team experience adapting to rapid growth in data volume and the increasing frequency of interim assessments; and another validating a comprehensive patient burden algorithm to optimize protocol design.

In collaboration with the Bill & Melinda Gates Medical Research Institute, we will launch a global survey in late January assessing remote team effectiveness and efficiency managing drug development activity. We'll send out invitations to participate in this important survey shortly.


Several CSDD studies are underway looking at diversity and inclusion: One quantifying participant demographic diversity in drug and biologic approvals by the European Medicines Agency and another study looking at the diversity of global investigative site personnel and ways to better enable their involvement and success in clinical research.

This Insider is a good place to find highlights and updates on Center activity. I also encourage you to visit our **website** periodically for more information and to get involved in our programs and studies. As always, we welcome your ideas, input and feedback.

Given growing demand for robust, evidence-based inquiry to improve drug development performance, efficiency and economics, the work of the Tufts Center could not be more important or relevant.

Wishing all of you a healthy, prosperous and meaningful new year.

Kenneth Getz Director and Professor



Working Group Studies



Working Group Study to Benchmark Global Investigative Site Diversity

In December, Tufts CSDD kicked off a new study benchmarking diversity and disparities among the global community of investigative sites involved with industryfunded clinical trials. Twenty companies sponsors and CROs— have already joined

the working group, and there is room for more. Contact us for more information.

New Working Group Study to Identify Best Practices in the Adoption of Innovations Supporting Clinical Operations

In late January and early February, Tufts CSDD is launching a new working group study looking at how sponsors and CROs adopt new and transformational practices



and solutions to support clinical research operations. The study will identify best practices and opportunities to accelerate innovation adoption. **Contact us for more information.**

Global Surveys



New Global Survey Assessing Remote Team Effectiveness in Managing Clinical Research Activity

This month, Tufts CSDD— in collaboration with the Bill & Melinda Gates Medical Research Institute—will launch a global survey to assess how the remote management of clinical research activity impacts study team interactions, productivity, overall performance and continuity.

We encourage the clinical research community to take part in this important survey. If you are interested in receiving a link to the online survey when it is launched, **please provide your contact information.**

Professional Development Courses



Health Economics and Outcomes Research (HEOR) Certificate Program

The Tufts University Graduate School of Biomedical Sciences (GSBS) Clinical and Translational Science (CTS) Graduate Program offers an accredited Certificate Program in Health Economics and Outcomes Research (HEOR).

Individuals seeking an introduction to HEOR, including professionals in the pharmaceutical and biotechnology industry, clinicians and other health care professionals, graduate degree holders, and graduate degree students, are encouraged to apply.

The Program is designed to accommodate the schedules of learners who are already immersed in professional careers or other training programs. There are three courses:

- Introduction to Health Economics and Outcomes Research (2 credits)
- Health Technology Assessment (HTA) (2 credits)
- Real World Evidence (1 Credit)

Learn more and apply for January 2021 semester



Tufts CSDD Partnership with The American College of Greece (ACG)

ACG Professional Certificate in Clinical Pharmacology, Drug Development and Regulation

Tufts Center for the Study of Drug Development is excited to collaborate with The American College of Greece to offer an online version of its highly acclaimed Postgraduate Course in Clinical Pharmacology, Drug Development and Regulation. This new two-week, intensive, live-interactive program offers a Professional Certificate in Clinical Pharmacology, Drug Development and Regulation from the Deree – School of Graduate and Professional Education.

Learn more and register online

Research Highlights

Our Latest *Impact Report*

VOLUME 22, NUMBER 6 | November/December 2020 Tufts Center for the Study of Drug Development REPORT INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES Global clinical trials transition to decentralized

models abruptly, in nuanced ways

mic began, over half of all active trials are using rem Telemedicine is the most frequently used approach to conducting decentralized clinical to

- stigative sites conducting remote trials rate patient safety as their greate
- Clinical trial volunteers report increased satisfaction when participating remotely.
- For many developers, particularly smaller organizations, contract service organizations have be primary provider of remote monitoring personnel and capabilities. · 54% of current clinical trials have adopted remote monitoring, despite cl
- 60% of investigative sites report having no prior experience with rem the second.

Transition to Decentralized Clinical Trials during the Coronavirus Pandemic is Far More Nuanced than Expected

Our November/December 2020 Tufts CSDD *Impact Report* presents results of our analysis of global surveys of investigative sites and interviews with representatives of the largest pharmaceutical companies.

Learn more | Purchase online

*Coming in Early January: **Rising Protocol Design Complexity Driving Rapid Growth in Clinical Data Volume**

Individual subscription | Corporate subscription

Recent Publications

Getz K. Public Trust and the 'Last Mile' for COVID-19 Vaccines. Applied Clinical Trials. 2020; 29 (12): 11 – 12. Access article

Gottlieb, N, Byrne, J, Getz, K. Investigative Site Placement Practices to Support Operation Warp Speed. 2020; 29 (12): 26-28. Access article

Raj Indupuri, Sheila Rocchio, Kenneth A. Getz, Beth Harper, Michael Wilkinson. Enabling Digital Transformation: Managing External Clinical Data Sources to Advance Drug Development. Applied Clinical Trials 2020; November 13. Access article

Stephen LeBreton, Mary Jo Lamberti, Adam Dion, Kenneth A. Getz. COVID-19 and Its Impact on the Future of Clinical Trial Execution. Applied Clinical Trials 2020; October 22. Access article

Galson S, Austin C, Khandekar E, Hudson L, DiMasi J, Califf R, Wagner J. The Failure to Fail Smartly. Nature Reviews Drug Discovery 2020; Sep 23. Published online: Access article

Harper B, Wilkinson M, Indupuri R, Rocchio S, Getz, K. Evolving Clinical Data Strategies and Tactics in Response to Digital Transformation. Ther Innov Regul Sci 2020; Sep 14.

Access article

DiMasi, J.A. Research and Development Costs of New Drugs [Letter to the Editor]. *JAMA* 2020; 324(5):517. Access article

Cameron D, Willoughby C, Messer D, Lux M, Aitken M, Getz K. Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. *Clinical Therapeutics* 2020; 42(8):e150-e159. Access article

Faculty and Staff Presentations

Recent Presentations

Town Hall: Where R&D Meets WFH

Ken Getz, MBA Copyright Clearance Center Online | December 15

Trials and Tribulations of Antimicrobial Drug Development: Assessing the Economic and Political Landscape

Kenneth I Kaitin, PhD Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance Seminar Online | December 17

Leveraging Patient and Participant Input to Optimize

Protocol Design Ken Getz, MBA Trial Innovation Network Online | January 4

Upcoming Presentations

Predictive Dosing to Reduce Clinical Trial Risk Ken Getz, MBA xTalks Online | February 10




TRIAL INNOVATION NETWOR

Subscriptions, Papers and Books









Purchase Impact Reports

Download White Paper

Become a Corporate Sponsor or donate to support our critical mission of providing data-driven analysis and strategic insight to improve the efficiency and productivity of pharmaceutical development.

About Tufts CSDD

Support Tufts CSDD

Tufts Center for the Study of Drug Development 75 Kneeland Street, Suite 1110 Boston, MA 02111 617-636-2170

